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Abstract
Background: Despite of the recent success of EGFR inhibitory agents, the primary drug-resistant
becomes a major challenge for EGFR inhibitor therapies. PTEN gene is an important positive
regulatory factor for response to EGFR inhibitor therapy. Low-expression of PTEN is clearly one
of the important reasons why tumor cells resisted to tyrosine kinase inhibitors.
Methods: To investigate the drug-resistance reversal to gefitinb and the mechanism in PTEN low
expression cells which radiated with X-rays in vitro, We demonstrated that H-157 lung cancer cells
(low-expression of PTEN but phospho-EGFR overexpressed tumor cells) exposed to X-rays. The
PTEN expressions and radiosensitizing effects of tyrosine kinase inhibitor before and after
irradiation were observed. The cell-survival rates were evaluated by colony-forming assays. The cell
apoptosis was investigated using FCM. The expressions of phospho-EGFR and PTEN were
determined by Western blot analysis.
Results: The results showed that the PTEN expressions were significantly enhanced by X-rays.
Moreover, the cell growth curve and survival curve were down-regulated in the gefitinib-treated
groups after irradiation. Meanwhile, the radiation-induced apoptosis of tumor cells was increased
by inhibition of the EGFR through up-regulation of PTEN.
Conclusion: These results suggested that PTEN gene is an important regulator on TKI inhibition,
and the resistance to tyrosine kinase inhibitors might be reversed by irradiation in PTEN low
expression cancer cells.
Background
The EGFR is a receptor tyrosine kinase that regulates fun-
damental processes of cell growth and differentiation.
Overexpression of EGFR and its ligands, were reported for
various epithelial tumors in the 1980s [1,2] and generated
interest in EGFR as a potential target for cancer therapy [3-
9]. These efforts have been rewarded in recent years as ATP
site-directed EGFR tyrosine kinase inhibitors has shown
anti-tumor activity in subsets of patients with non-small
cell lung cancer [10,11], squamous cell carcinomas of the
head and neck [12], and selected other malignancies [13-
17]. The current data from retrospectively analyzed clini-
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cal trials and preclinical models [18-23] suggested that
monotherapy with EGFR kinase inhibitors is unlikely to
be effective in PTEN-deficient tumors, even if they harbor
activating EGFR mutations. This could potentially result
in upfront resistance to EGFR inhibitors in highly PTEN-
deficient tumors. However, there are little research on the
drug-resistance of EGFR kinase inhibitors, and there is no
suitable means for reversal of drug resistance in clinical
practice until today. The data presented herein describe
the resistance to tyrosine kinase inhibitors (TKI) reversed
on PTEN low-expression cancer cells by irradiation in
vitro. Our study may have potential impacts on the clini-
cal applications of combining TKI with irradiation ther-
apy in patients with cancers of primary drug-resistance to
TKI.
Materials and methods
Reagents
Cell culture media was provided by Tianjin Medical Uni-
versity Cancer Institute (Jin-pu Yu, MD). Primary antibod-
ies against phospho-EGFR and PTEN were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); Propid-
ium Iodide (PI) and annexin V were purchased from Cell
Signaling Company (Cell Signaling Technology, Beverly,
MA). Gefitinib was generously provided by AstraZeneca
(Zhen-yu You, Beijing). All the other materials were from
Cancer Institute of our university.
Cell lines and cell culture
The H-157 lung cancer cell line was kindly provided by
Peking University Center for Human Disease Genomics. It
was maintained in RPMI1640 supplemented with 20 mM
HEPES (pH 7.4), 100 IU/mL penicillin, 100 mg/mL strep-
tomycin, 4 mM glutamine and 10% heat-inactivated fetal
bovine serum (Hangzhou Sijiqing Biological Engineering
Materials Company, China) in a humidified atmosphere
of 95% air and 5% CO2 at 37°C.
Ionizing radiation treatment
Exponentially growing H-157 cells in a tissue-culture flask
(75 cm2) were irradiated by an X-ray generator with a 1.0-
mm aluminum filter at 200 kVp and 10 mA, at a dose of
1.953 Gy/min, which was determined using Fricke's
chemical dosimeter. Then they were incubated for
another 48 h at 37°C. Addition of Gefitinib was carried
out at the same time when the treatment of irradiation
was performed. Radiation was performed in the Tianjin
Medical University Cancer hospital.
Western blot analysis
To examine the phospho-EGFR and PTEN expression in
H-157 cells, the protein was assayed by western blot anal-
ysis [24]. To determine whether irradiation causes an
increase of PTEN expression, cells in culture were irradi-
ated with 1, 2, 4, 6, 8 and 10 Gy. Following treatment, the
cells were collected 3 h, 6 h, 9 h, and 12 h respectively.
Total protein was extracted from H-157 cancer cell lines,
resolved and analyzed by Western blotting. In brief, cells
were washed with cold-phosphate buffered saline (PBS),
scraped in RIPA buffer (100 mMTris, 5 mMEDTA,
5%NP40, pH8.0) containing protease inhibitors cocktail
(Roche diagnostics, Mannheim, Germany) and allowed
for at least 30 min on ice. Cells were subjected to further
analysis by one freeze-thaw cycle and centrifuged at
14,000 g for 30 min at 4°C. Supernatants were carefully
removed and protein concentrations were determined by
Bio-Rad-DC protein estimation kit. Electrophoresis was
performed on polyacrylamide gel (10%) using equal
amounts of protein samples under reducing conditions.
Resolved proteins were transferred to the PVDF mem-
branes and probed with primary antibodies followed by
incubation with corresponding horseradish peroxidase-
conjugated secondary antibodies. Signal was detected
with ECL electrochemiluminescence (ECL) Kit (Amer-
sham Biosciences).
Cell-growth analysis
Cell proliferation was determined by assessing the mito-
chondrial reduction of MTT. In brief, cells from the con-
trol and gefitinib-pre-treated groups were plated at 1 × 103
cells/well in 96-well plates containing 200 μL growth
medium and allowed to attach for 24 h. The medium was
removed, and the gefitinib-treated cells were quiesced for
2d in a medium supplemented with100, 500, 1000 nM
gefitinib. The medium was changed on day 2 of the 4d
experiment. At harvest, the medium was removed from
the appropriate wells, replaced with 50 μL MTT solution
(2.5 mg MTT/ml), and incubated for 4 h at 37°C. After
incubation, the MTT solution was carefully aspirated and
replaced with 150 μL DMSO. Cell growth was analyzed on
a plate reader by using SoftMax program (Molecular
Devices Corp., Menlo Park, CA). Experiments were per-
formed in quadruplicate and repeated at least 3 times. At
the same time, the antiproliferative effect of gefitinib on
the growth profile in vitro of H-157 cell line was exam-
ined. Briefly, The cells were treated with different concen-
trations of gefitinib (100, 500, 1000 nM). The control and
gefitinib-treated cells(1 × 104/well) were seeded on 6-well
plates, and proliferation was evaluated by cell counting
using a hemocytometer after 1,2,3,4,5,6 and 7 days of cul-
ture. All measurements were done in triplicate [25,26].
The methods were also used to detect the antiproliferative
effect of gefitinib after irradiation.
Clonogenic survival
Clonogenic survival was the ability of cells to maintain
clonogenic capacity and to form colonies. The treatment
schedule for clone assay: there are 4 groups in the experi-
ments (the control, irradiation and/or gefitinib-treated
groups). Cells in culture were irradiated with 1, 2, 4, 6, 8Journal of Experimental & Clinical Cancer Research 2009, 28:123 http://www.jeccr.com/content/28/1/123
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and 10 Gy, and the gefitinib concentration was 100 nM.
Briefly, after exposure to radiation, cells were trypsinized,
counted, and seeded for colony formation in 60 mm
dishes at 200 to 10000 cells/dish. After incubation inter-
vals of 14 to 21 days, colonies were stained with crystal
violet and manually counted. Colonies consisting of 50
cells or more were scored. Experiments were done in trip-
licate [27].
Detection of apoptotic cells by FCM
To examine whether enhancement of apoptosis in X-ray
irradiated H-157 cells overexpressed with PTEN was asso-
ciated with gefitinib, we tested the effects of EGFR inhibi-
tors on the enhancement of apoptosis in H-157 cells with
and without irradiation. Cells from the irradiation and
combined with Gefitinib groups (100 nM) were exposed
to the same radiation dosages (6 Gy). At 48 h after irradi-
ation, the cells were harvested. And then, cells were
trypsinized, counted, and washed twice with cold PBS.
Cells used for tests were stained with propidium iodide
(PI) and annexin V for 15 min in the dark and analyzed
by fluorescence-activated cell sorting (FACS) using Coul-
ter EPICS and ModFit software (Verity Software House,
Topsham, MN). Each test was performed 3 times [28].
Statistical analysis
Data was plotted as means ± standard deviation. Student's
t test was used for comparisons. Differences were consid-
ered significant at P < 0.05.
Results
EGFR, PTEN expression of H-157 cells
It was reported that H-157 cells might be overexpression
of phospho-EGFR and low-expression of PTEN [18]. In
the present study, we confirmed the expression of phos-
pho-EGFR and PTEN on the cells by western blotting. H-
157 cells expressed high level of phospho-EGFR, but
PTEN was low expressed. Both the phospho-EGFR and
PTEN highly expressed cells, the A431 cells, were taken as
positive control (Figure 1).
Effects of gefitinib on H-157 cell growth
As shown in Figure 2, though different concentrations
treatment produced no significant inhibition to H-157
cell growth. Cell counting was also used to assess the pro-
liferative ability of gefitinib-treated cells. There was no sig-
nificant difference in the growth rates between control
cells and gefitinib-treated cells.
Expression of PTEN in H-157 cells after irradiation 
treatment
After different dosage radiation (0, 1, 2, 4, 6, 8, and 10
Gy), the PTEN expression increased in a time-dependent
manner. The highest expression were observed in H-157
cells treated with 4~6 Gy irradiation. At the same time, we
also measured that PTEN expression increased at 3 h and
returned to baseline at 12 h after irradiation (Figure 3).
Based on this, we concluded that 6 Gy was the best dosage
for improving PTEN expression and the same time as
treatment with irradiation was the optimal time for addi-
tion of gefitinib.
Survival curve and cell growth curve of gefitinib-treated H-
157 cells after irradiation
The cloning efficiency of H-157 was between 60% and
90%. The survival curve of control and gefitinib-treated H-
157 cells after irradiation was shown in Figure 4. The radi-
obiological parameters of H-157 cells treated with irradi-
ation and gefitinib were D0 = 1.14, Dq = 0.22, N = 1.57,
while those of irradiation-treated H-157 cells were D0 =
1.51, Dq = 0.88, N = 3.84. In the present study, SER (sen-
sitive enhancement ratio) = D0 (irradiation+gefitinib
group)/D0 (irradiation group) = 1.51/1.14 = 1.32. The
SER in gefitinib-treated cells indicated that treatment with
gefitinib significantly improved the biological effect of
irradiation following PTEN high expressed. At the same
time, the cell growth curve was also down-regulated by
gefitinib after irradiation (Figure 4). The data presented
herein suggested the resistance for gefitinib was reversed
by irradiation in H-157cells.
Expressions of EGFR and PTEN in H-157 cells Figure 1
Expressions of EGFR and PTEN in H-157 cells. West-
ern blots of EGFR (upper panel) and PTEN (lower panel) in 
H-157 cells. Both the EGFR and PTEN highly expressed cells, 
A431 cells, were taken as positive control.Journal of Experimental & Clinical Cancer Research 2009, 28:123 http://www.jeccr.com/content/28/1/123
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Effects of gefitinib on H-157 cell growth in vitro Figure 2
Effects of gefitinib on H-157 cell growth in vitro. (A)Cell proliferation was determined by assessing the mitochondrial 
reduction of MTT. Bars indicated means ± standard deviation of three independent experiments performed in triplicate (n = 
9). Compared with untreated control cells, P > 0.05 were found in all of the treated groups. (B)Known numbers of single cells 
were plated into culture dishes in RPMI1640 containing 10% FBS and treated with gefitinib in several doses. Cells were then 
harvested by trypsinization and counted by a hemocytometer with trypan blue dye. Data points mean of triplicate samples. 
Data were expressed as means ± SE for three experiments. P> 0.05 vs. control group by Student's t-test was found in every 
treated group.Journal of Experimental & Clinical Cancer Research 2009, 28:123 http://www.jeccr.com/content/28/1/123
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Gefitinib increased the radiation-induced apoptosis
As shown in Figure 5. The early apoptosis rate among
gefitinib-treated H-157 cells after 6 Gy irradiation was sig-
nificantly higher than the cells with the same dosage of X-
rays only. Whereas, no significant apoptotic changes were
observed in unirradiated cells before and after gefitinib
treated. Quantitative measurements of apoptotic cell
death by FCM in H-157 cells sufficiently indicated that the
radiation-induced overexpression of PTEN significantly
enhanced gefitinib-induced apoptosis in comparison with
that of the control (no irradiation).
Discussion
The PI3K pathway is a critical effector of growth, prolifer-
ation, and survival pathways. PTEN serves as negative reg-
ulator of the phosphatidylinositol 3-kinase (PI3K)
pathway by removing the third phosphate from the inosi-
tol ring of the second messenger PIP3 [29]. PTEN inacti-
vation results in accumulation of PIP3 levels and
persistent signaling through the serine/threonine kinase
Akt/protein kinase B. PTEN loss could thus promote
resistance to EGFR kinase inhibitors from downstream
inhibition of the PI3K signaling pathway [30-35]. Con-
sistent with this, increased levels of PTEN expression is
considered as basic principle during reversal of resistance
for tyrosine kinase inhibitors in patients with PTEN low-
expression cancers. In order to improve PTEN expression,
transfection by medium such as plasmid and virus is the
common method in fundamental research [36-39]. How-
ever, in the clinical application, these methods have been
unable to overcome its own errors and defects, for
instance, transfection efficiency, distribution in vivo, and
so on. Finding the effective methods which can reverse
primary drug-resistance in PTEN low-expression cells has
become the urgent task on targeted therapy in clinical
practice.
As the drug resistant cell line for tyrosine kinase inhibitors
due to low expression level of PTEN protein [18], H-157
cell line is the precondition of the experiment. Our results
demonstrated that phospho-EGFR higher expression and
low-expression of PTEN present in H-157 cells (Fig. 1),
which are accorded with the reports of literatures [18]. We
also observed that when the H-157 cells were exposed to
gefitinib, no significant deference of cell growth curve
(Fig. 2), and no increase in the apoptosis of cells was
found (Fig. 5). In conclusion, findings from the present
study indicated that gefitinib has no effective antiprolifer-
ative function for H-157 cells. As a safe and satisfied
method in the clinical therapy of cancer, Irradiation is
easy to obtained, and it has not the disadvantages such as
maldistribution and low transfer efficiency of transfec-
tion. Compared with transfection, irradiation possesses
incomparable superiority, and it is one of the best solu-
tions of drug-resistant reversal for TKI therapy [40,41].
Meanwhile, our results indicated that exposure to gefit-
inib after radiation enhanced the radiosensitivity of H-
157 cells (Fig. 4). Considering that an increase in the level
of the PTEN expression, the negative regulator of the
phosphatidylinositol 3-kinase (PI3K) pathway was
increased after irradiation, and then the second messenger
PIP3 levels decreased, further activation of the serine/thre-
onine kinase Akt/protein kinase B declined. So, the cell
proliferation decreased and the cell death increased [29].
Therefore, x-ray radiation might play a major role in the
drug-resistance reversal.
It must point out that cross talk between different path-
ways makes miscellaneous of signal transductions in
tumor cells. Up to now, it is still unclear that whether
there exist other factors of PI3K pathway producing influ-
ence for tyrosine kinase inhibitors efficacy except for
PTEN protein. Whether the factors are influenced by irra-
diation, and then made some effect on the drug-resistance
further remains unknown. These all need further research
on PI3K pathway.
Expression of PTEN in H-157 cells after irradiation treat- ment Figure 3
Expression of PTEN in H-157 cells after irradiation 
treatment. (A) The H-157 cells which exposed to 1, 2, 4, 6, 
8, and 10 Gy of X-rays were analyzed as shown in right panel. 
After irradiation, the cells were incubated for 6 h, and then 
were examined. (B) After incubation of X-irradiated (6 Gy) 
cells for 3, 6, 9 and 12 h, the PTEN protein was examined by 
Western blotting. Irradiation Treatment was shown to 
increase PTEN levels in H-157 cell lines tested, and H-157 
cells exposing to 4~6 Gy expressed major amounts of PTEN.Journal of Experimental & Clinical Cancer Research 2009, 28:123 http://www.jeccr.com/content/28/1/123
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Irradiation reversed the resistance of H-157 cells to gefitinib Figure 4
Irradiation reversed the resistance of H-157 cells to gefitinib. (A) Clonogenic survival curves for gefitinib and/or radia-
tion treatments in H-157 cells. Cells attached to the flasks were treated with 100 nmol/L gefitinib, meanwhile, irradiated with 
graded doses of x-rays, rinsed after 48-hour incubation in drug-containing medium, and allowed to form colonies in drug-free 
medium. Surviving fractions for radiation + gefitinib were normalized by dividing by the surviving fraction for gefitinib only. Each 
test was performed 3 times. The radiation-enhancing (t = 7.65, P < 0.01) effect of gefitinib was comparable with that of gefitinib 
alone in H-157 cells. (B) Effects of gefitinib on H-157 cell growth after irradiation. There was no significant difference (t = 1.13, 
P > 0.05) in the growth rates between H-157 cells and gefitinib-treated cells as determined by cell counting, but the prolifera-
tive ability of the gefitinib and radiation treated cells was dramatically suppressed(t = 5.01, P < 0.05)in contrast with radiation-
treated only.Journal of Experimental & Clinical Cancer Research 2009, 28:123 http://www.jeccr.com/content/28/1/123
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Conclusion
Our study provides a new idea for drug-resistance reversal
of TKI targeted therapy, and makes a beneficial explora-
tion on tyrosine kinase inhibitors combined with radio-
therapy in TKI resistant tumors. We believe that, with the
further development of fundamental research, we are
looking forward to an increasing application prospect of
tyrosine kinase inhibitors in clinical practice.
List of abbreviations
EGFR: epidermal growth factor receptor; PE: plating effi-
ciency; SF: survival fraction; RBE: relative biological effect;
D0; mean lethal dose; Dq: quasithreshold dose; N: extrap-
olation number; MTT: methyl thiazolyl tetrazolium; FCM:
flowcytometry;  TKI: tyrosine kinase inhibitor; PTEN:
phosphatase and tensin homolog on chromosome ten;
PIP3: phosphatidyinositol-3, 4, 5- triphosphate; PI3K:
phosphatidylinositol-3-kinase.
Gefitinib-induced apoptosis in H-157 cells before and after irradiation Figure 5
Gefitinib-induced apoptosis in H-157 cells before and after irradiation. Attached cells were exposed to 6 Gy irradia-
tion and then treated with 100 nmol/L gefitnib. After additional 48-hour incubation in medium containing the drugs, the cells 
were harvested. The apoptotic index (AI) was measured using flow cytometry. (A) Control groups (AI: 1.36 ± 0.74%). (B) 
Apoptotic values after treatment with 100 nmol/L gefitinib alone (AI:3.58 ± 0.61%).(C) Radiation- induced apoptosis induction 
(14.26 ± 2.97%% of total cells) in H-157 cells.(D) Radiation combined with gefitinib induced apoptosis induction (23.58 ± 3.61% 
of total cells). Apoptotic values were normalized by subtracting control values; the normalized apoptotic values were used for 
statistical analyses. Experiments were done in triplicate. Combined drug treatments were shown to enhance radiation-induced 
apoptosis in H-157 cells (t = 19.91, P < 0.01), but no synergistic manner when compared with drug alone without radiation (t 
= 2.569, P > 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:123 http://www.jeccr.com/content/28/1/123
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